X0306 4 2018-01-07 0 0000827871 EAGLE PHARMACEUTICALS, INC. EGRX 0001637347 Hepner Adrian C/O EAGLE PHARMACEUTICALS, INC. 50 TICE BLVD., SUITE 315 WOODCLIFF LAKE NJ 07677 0 1 0 0 EVP and Chief Medical Officer Common Stock 2018-01-07 4 A 0 9000 0.00 A 9000 D Employee Stock Option (Right to Buy) 59.14 2018-01-07 4 A 0 43000 0.00 A 2028-01-06 Common Stock 43000 43000 D Performance Stock Unit 2018-01-07 4 A 0 27000 0.00 A 2021-01-01 Common Stock 27000 27000 D These shares were issued pursuant to a restricted stock unit ("RSU") award, each RSU representing a contingent right to receive one share of the Issuer's common stock. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of January 7, 2018, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. The option vests over a period of four years, with 25% of the shares underlying the option vesting on January 7, 2019, the first anniversary of the date of grant, and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock. Represents the maximum number of shares issuable under this award. The shares issuable in respect of such PSUs shall vest on the three-year anniversary of January 1, 2018 (such three-year anniversary, the "Vesting Date"), based on the extent to which the following stock price hurdles are achieved for 30 consecutive trading days on or prior to the Vesting Date. If the Issuer's stock price reaches or surpasses $85.92, $110.00, $120.00 or $134.25, then 9,000, 18,000, 22,500 or 27,000 PSUs will vest, respectively. The number of shares issuable in respect of such PSUs vested on the Vesting Date will be determined by the highest Issuer stock price hurdle achieved. This vesting is subject to the Reporting Person's continuous service with the Issuer as of the Vesting Date. /s/ Scott Tarriff, Attorney-in-Fact 2018-01-09